Source: International Congress 2019 – Granulomatous disorders: pathogenesis, epidemiology and clinical issues
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
P. Cameli (Siena, Italy), L. Bergantini (Siena, Italy), F. Bianchi (Siena, Italy), M. Mazzei (Siena, Italy), P. Sestini (Siena, Italy), P. Rottoli (Siena, Italy), E. Bargagli (Siena, Italy). Biomarkers of Sarcoidosis: a comparative study of serum chitotriosidase, ACE, lysozyme and KL-6. 1959

Member's Comments

No comment yet.

Related content which might interest you: Study of angiotensin-converting enzyme, serum amyloid A, soluble interleukin-2 receptor, lysozyme and KL-6 in serum as diagnostic markers in pulmonary sarcoidosis Source: Annual Congress 2007 - Sarcoidosis: various aspects Year: 2007 Comparative study of CC16, KL-6 and SP-D as serum markers in sarcoid patients Source: Eur Respir J 2002; 20: Suppl. 38, 173s Year: 2002 Serum levels of chitotriosidase in pulmunary sarcoidosis Source: Annual Congress 2008 - COPD and other environment-related lung diseases Year: 2008 Serum KL-6, SP-D and MMP-2 as diagnostic biomarkers in asbestosis and silicosis Source: International Congress 2017 – Silicosis has not gone away Year: 2017 The evaluation of serum biomarkers in patients with sarcoidosis: Can visfatin be a new biomarker for sarcoidosis? Source: International Congress 2017 – Rare diseases Year: 2017 YKL-40, soluble IL-2 receptor, ADA and neopterin: comparison of markers of sarcoidosis activity Source: Annual Congress 2009 - Sarcoidosis in review Year: 2009 Elevated circulating concentrations of adiponectin in sarcoidosis – a new marker of disease? Source: Annual Congress 2006 - Clinical features and disease markers of sarcoidosis Year: 2006 Human napsin a is a useful serum marker of interstitial lung disease, compared to KL-6, and surfactant protein-D Source: Annual Congress 2009 - Bronchoalveolar lavage and phenotyping in diffuse parenchymal lung disease Year: 2009 Serum KL-6 as a biomarker for interstitial lung diseases in a clinical setting: application of a fully automated immunoassay. Source: International Congress 2019 – Biomarkers of idiopathic interstitial pneumonia Year: 2019 The effect of exercise on serum amyloid a levels in patients with sarcoidosis: A preliminary report Source: International Congress 2015 – Sarcoidosis: pathogenesis Year: 2015 Elevation of serum napsin A levels in patients with hypersensitive pneumonia Source: Annual Congress 2013 –Diffuse parenchymal lung disease I Year: 2013 Serum KL-6 as a marker of disease progression in SSc-ILD Source: International Congress 2018 – CTD-ILD and hypersensitivity pneumonitis: from the bench to the bedside Year: 2018 Serum TNFα, CD14 and CRP levels in COPD patients with different alpha-1 antitrypsin phenotypes Source: Annual Congress 2008 - Advances in functional genomics of neoplastic and non-neoplastic lung diseases Year: 2008 The serum YKL-40 is a useful biomarker for asthma Source: International Congress 2017 – Techniques to treat asthma Year: 2017 High serum levels of YKL-40 in IPF Source: Annual Congress 2008 - Novel mechanisms and targets of molecular pulmonary pathology Year: 2008 Human chitotriosidase analysis: a reliable biomarker of sarcoidosis severity Source: International Congress 2017 – The many faces of sarcoidosis Year: 2017 Circulating d-Dimer lysozyme and angiotensin-converting enzyme in active sarcoidosis Source: Eur Respir J 2001; 18: Suppl. 33, 196s Year: 2001 Usefulness of inflammatory markers: procalcitonin, neopterin, C-reactive protein and MR-proANP in the follow-up of patients with chronic obstructive pulmonary disease Source: Annual Congress 2008 - Biomarkers and antibiotic treatment of exacerbations of COPD Year: 2008 Concentration of C-reactive protein (CRP) in elderly asthmatics Source: International Congress 2015 – Clincal aspects of asthma: monitoring and mechanisms Year: 2015 Significance of serum YKL-40, S100A8, S100A9, calprotectin, periostin and LRG1 levels in patients with newly diagnosed, controlled and uncontrolled asthma Source: International Congress 2018 – Clinical determinants and biomarkers of COPD Year: 2018